Related Experiment Videos
Therapeutic update on glycopeptide and lipopeptide antibiotics
J C Rotschafer1, M W Garrison, K A Rodvold
1Section of Clinical Pharmacology, St. Paul-Ramsey Medical Center, MN 55101.
Abstract:
Glycopeptide antibiotics in the form of vancomycin have been available for almost 30 years. In the past, vancomycin usually was reserved as an alternative agent to treat staphylococcal and streptococcal infection in patients with a penicillin allergy or hemodialysis shunt infection. With the increasing frequency of both methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis, now it is often used as a first-line agent. Over a 10-year period, vancomycin sales have increased by almost $1 hundred million. Several new glycopeptide and lipopeptide antibiotics are in various stages of evaluation. While vancomycin resistance to date is a rare phenomenon, these drugs represent a potentially more potent and safer antibiotic alternative to vancomycin. Teicoplanin and daptomycin are two of these investigational agents.
Insights
Vancomycin, a glycopeptide antibiotic, is increasingly used for resistant bacterial infections. New alternatives like teicoplanin and daptomycin offer potentially safer and more potent treatment options.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Vancomycin, a glycopeptide antibiotic, has been a clinical option for nearly three decades.
- Historically, vancomycin was a secondary choice for specific infections, particularly in penicillin-allergic patients.
- The rise of antibiotic resistance, notably methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis, has elevated vancomycin's status to a first-line treatment.
Purpose of the Study:
- To review the evolving role of vancomycin in treating bacterial infections.
- To highlight the increasing clinical reliance on vancomycin due to resistant pathogens.
- To introduce emerging glycopeptide and lipopeptide antibiotics as potential alternatives.
Main Methods:
- Literature review of vancomycin usage and sales trends over a decade.
- Analysis of the current landscape of antibiotic resistance.
- Overview of investigational glycopeptide and lipopeptide antibiotics.
Main Results:
- Vancomycin sales increased by nearly $100 million over a 10-year period, reflecting increased usage.
- Methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections are driving the increased use of vancomycin.
- Several new glycopeptide and lipopeptide antibiotics are under development.
Conclusions:
- Vancomycin remains a critical antibiotic, but its increased use necessitates exploring alternatives.
- Emerging antibiotics such as teicoplanin and daptomycin show promise as more potent and safer options than vancomycin.
- While vancomycin resistance is currently rare, the development of new agents is crucial for future therapeutic strategies.